• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mathematical Models to Characterize the Absorption, Distribution, Metabolism, and Excretion of Protein Therapeutics.用于描述蛋白质治疗药物的吸收、分布、代谢和排泄的数学模型。
Drug Metab Dispos. 2022 Jun;50(6):867-878. doi: 10.1124/dmd.121.000460. Epub 2022 Feb 23.
2
Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives.治疗性蛋白的吸收、分布、代谢和排泄:当前行业实践与未来展望。
Drug Metab Dispos. 2022 Jun;50(6):837-845. doi: 10.1124/dmd.121.000461. Epub 2022 Feb 11.
3
The absorption, distribution, metabolism and elimination characteristics of small interfering RNA therapeutics and the opportunity to predict disposition in pregnant women.小干扰RNA疗法的吸收、分布、代谢和消除特征以及预测其在孕妇体内处置情况的机会。
Drug Metab Dispos. 2025 Jan;53(1):100018. doi: 10.1124/dmd.123.001383. Epub 2024 Nov 22.
4
Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.基于生理的药代动力学建模工具的开发与应用以支持药物发现。
Chem Biodivers. 2005 Nov;2(11):1462-86. doi: 10.1002/cbdv.200590119.
5
Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.药物发现与开发中基于生理学的单克隆抗体药代动力学建模。
Drug Metab Pharmacokinet. 2019 Feb;34(1):3-13. doi: 10.1016/j.dmpk.2018.11.002. Epub 2018 Nov 22.
6
Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview.siRNA 治疗药物的药代动力学和药效学建模——综述
Pharm Res. 2022 Aug;39(8):1749-1759. doi: 10.1007/s11095-022-03333-8. Epub 2022 Jul 12.
7
Factors Influencing ADME Properties of Therapeutic Antisense Oligonucleotides: Physicochemical Characteristics and Beyond.影响治疗性反义寡核苷酸ADME特性的因素:物理化学特性及其他
Curr Drug Metab. 2023;24(7):536-552. doi: 10.2174/1389200224666230418092626.
8
The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of -Acetylgalactosamine-Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human.-乙酰半乳糖胺偶联的小干扰 RNA 的非临床处置和药代动力学/药效学特性具有高度可预测性,为向人体转化建立了信心。
Drug Metab Dispos. 2022 Jun;50(6):781-797. doi: 10.1124/dmd.121.000428. Epub 2021 Jun 21.
9
Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling of Nanomaterials.基于生理学的纳米材料药代动力学(PBPK)建模进展。
ACS Pharmacol Transl Sci. 2024 Jul 12;7(8):2251-2279. doi: 10.1021/acsptsci.4c00250. eCollection 2024 Aug 9.
10
Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.美国食品和药物管理局批准的反义寡核苷酸药物的吸收、分布、代谢和排泄。
Drug Metab Dispos. 2022 Jun;50(6):888-897. doi: 10.1124/dmd.121.000417. Epub 2022 Feb 27.

引用本文的文献

1
Pharmacometric modeling of lipid nanoparticle-encapsulated mRNA therapeutics and vaccines: A systematic review.脂质纳米颗粒包裹的mRNA治疗药物和疫苗的药代动力学建模:一项系统综述。
Mol Ther Nucleic Acids. 2025 Aug 14;36(3):102686. doi: 10.1016/j.omtn.2025.102686. eCollection 2025 Sep 9.
2
Human nerve growth factor delivery to the retina: Quantitative methodology and mathematical modeling in preclinical settings.人神经生长因子向视网膜的递送:临床前环境中的定量方法和数学建模
PNAS Nexus. 2025 Aug 11;4(8):pgaf250. doi: 10.1093/pnasnexus/pgaf250. eCollection 2025 Aug.
3
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms.使用不同生理基于药代动力学建模平台的单克隆抗体处置预测比较。
J Pharmacokinet Pharmacodyn. 2024 Dec;51(6):639-651. doi: 10.1007/s10928-023-09894-4. Epub 2023 Nov 12.

本文引用的文献

1
Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings.治疗性单克隆抗体在临床前和临床环境中的异速缩放。
MAbs. 2021 Jan-Dec;13(1):1964935. doi: 10.1080/19420862.2021.1964935.
2
A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models.一种多价双特异性靶向表皮生长因子受体(EGFR)的纳米抗体药物偶联物在实体瘤模型中显示出强大的抗癌活性。
Signal Transduct Target Ther. 2021 Sep 3;6(1):320. doi: 10.1038/s41392-021-00666-5.
3
Imaging Reveals Importance of Shape and Flexibility for Glomerular Filtration of Biologics.影像学揭示形状和柔韧性对生物制剂肾小球滤过的重要性。
Mol Cancer Ther. 2021 Oct;20(10):2008-2015. doi: 10.1158/1535-7163.MCT-21-0116. Epub 2021 Jul 26.
4
A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade.一种双靶向抗体药物偶联物,用于治疗 MET 表达的癌症,包括那些对 MET 通路阻断无反应的癌症。
Mol Cancer Ther. 2021 Oct;20(10):1966-1976. doi: 10.1158/1535-7163.MCT-21-0009. Epub 2021 Jul 26.
5
A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab.建立群体生理药代动力学模型以描述儿科人群中抗体的处置特征,并采用英夫利昔单抗对该模型进行评估。
Br J Clin Pharmacol. 2022 Jan;88(1):290-302. doi: 10.1111/bcp.14963. Epub 2021 Jul 19.
6
FDA approves 100th monoclonal antibody product.美国食品药品监督管理局批准第100种单克隆抗体产品。
Nat Rev Drug Discov. 2021 Jul;20(7):491-495. doi: 10.1038/d41573-021-00079-7.
7
A Two-Pore Physiologically Based Pharmacokinetic Model to Predict Subcutaneously Administered Different-Size Antibody/Antibody Fragments.一种两孔生理基于药代动力学模型预测皮下给予不同大小的抗体/抗体片段。
AAPS J. 2021 May 3;23(3):62. doi: 10.1208/s12248-021-00588-8.
8
Top companies and drugs by sales in 2020.2020年销售额排名靠前的公司和药品。
Nat Rev Drug Discov. 2021 Apr;20(4):253. doi: 10.1038/d41573-021-00050-6.
9
Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis.使用微透析法测定大鼠体内抗转铁蛋白受体抗体亲和变体的脑药代动力学。
MAbs. 2021 Jan-Dec;13(1):1874121. doi: 10.1080/19420862.2021.1874121.
10
Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody.采用糖基化工程改造的治疗性单克隆抗体变体在大鼠模型中的糖型分辨药代动力学研究。
MAbs. 2021 Jan-Dec;13(1):1865596. doi: 10.1080/19420862.2020.1865596.

用于描述蛋白质治疗药物的吸收、分布、代谢和排泄的数学模型。

Mathematical Models to Characterize the Absorption, Distribution, Metabolism, and Excretion of Protein Therapeutics.

机构信息

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, New York.

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, New York

出版信息

Drug Metab Dispos. 2022 Jun;50(6):867-878. doi: 10.1124/dmd.121.000460. Epub 2022 Feb 23.

DOI:10.1124/dmd.121.000460
PMID:35197311
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11022906/
Abstract

Therapeutic proteins (TPs) have ranked among the most important and fastest-growing classes of drugs in the clinic, yet the development of successful TPs is often limited by unsatisfactory efficacy. Understanding pharmacokinetic (PK) characteristics of TPs is key to achieving sufficient and prolonged exposure at the site of action, which is a prerequisite for eliciting desired pharmacological effects. PK modeling represents a powerful tool to investigate factors governing in vivo disposition of TPs. In this mini-review, we discuss many state-of-the-art models that recapitulate critical processes in each of the absorption, distribution, metabolism/catabolism, and excretion pathways of TPs, which can be integrated into the physiologically-based pharmacokinetic framework. Additionally, we provide our perspectives on current opportunities and challenges for evolving the PK models to accelerate the discovery and development of safe and efficacious TPs. SIGNIFICANCE STATEMENT: This minireview provides an overview of mechanistic pharmacokinetic (PK) models developed to characterize absorption, distribution, metabolism, and elimination (ADME) properties of therapeutic proteins (TPs), which can support model-informed discovery and development of TPs. As the next-generation of TPs with diverse physicochemical properties and mechanism-of-action are being developed rapidly, there is an urgent need to better understand the determinants for the ADME of TPs and evolve existing platform PK models to facilitate successful bench-to-bedside translation of these promising drug molecules.

摘要

治疗性蛋白(TPs)是临床应用中最重要且发展最快的药物类别之一,但成功开发 TPs 常常受到疗效不理想的限制。了解 TPs 的药代动力学(PK)特征是在作用部位获得足够和持久暴露的关键,这是产生所需药理作用的前提。PK 建模是研究影响 TPs 体内处置因素的有力工具。在这篇综述中,我们讨论了许多最新的模型,这些模型可以重现 TPs 在吸收、分布、代谢/分解和排泄途径中的关键过程,并可以整合到基于生理学的 PK 框架中。此外,我们还就当前的机会和挑战提出了看法,以推进 PK 模型的发展,从而加速安全有效的 TPs 的发现和开发。

意义陈述

本篇综述概述了为表征治疗性蛋白(TPs)的吸收、分布、代谢和消除(ADME)特性而开发的机制性 PK 模型,这些模型可以支持 TPs 的基于模型的发现和开发。随着具有不同理化性质和作用机制的下一代 TPs 迅速发展,我们迫切需要更好地了解 TPs 的 ADME 决定因素,并改进现有的平台 PK 模型,以促进这些有前途的药物分子从实验室到临床的成功转化。